ClinicalTrials.gg
Not yet recruitingNCT07883590Updated Nov 13, 2026

A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS).

A Phase 1 interventional study of LY3873862 and CYP450 Drug Cocktail in Amyotrophic Lateral Sclerosis and Cytochrome P-450 Enzyme System, sponsored by Eli Lilly and Company. Not yet recruiting at 7 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

How we know

Updated Nov 13, 2026Newly registered5 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.

Planned enrollment
155th of 307
32 · median 33
Started
2026
with 32 others
Phase 1
57 of 440
11 open now
Primary completion
2027-11
later than 69 of 128 live
Registered
437th of 440
by date

Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 155th largest by planned enrollment of the 307 interventional ones that give a count, is one of 33 that started in 2026, is one of 57 in phase 1, reaches primary completion later than 69 of the 128 other live ones, and was the 437th registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, or all of them as a file.
02

Study summary

The main purpose of this study in participants with Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS) is to test the safety of different doses and to determine the amount of LY3873862 that gets into the bloodstream and how long it takes the body to get rid of it. For each participant, the study will last up to approximately 13 weeks and will include 6 clinic visits.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis
  • Cytochrome P-450 Enzyme System
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of sporadic or familial Amyotrophic Lateral Sclerosis (ALS) (definite, probable, laboratory probable) made by physician experienced with management of ALS as defined by the World Federation of Neurology revised El Escorial criteria.
  • Have an ALS symptom onset as determined by the investigator within 24 months of screening.
  • Have a within the range 18 to 35 kilograms per square meter (kg/m²) (inclusive).
  • Are individuals assigned male at birth (AMAB) or assigned female at birth (AFAB), including both individuals of (IOCBP) and individuals not of childbearing potential (INOCBP). use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Are able to safely swallow solids or liquids, or both.

Exclusion criteria

Exclusion Criteria:

  • Have a history or presence of medical illness that, in the judgment of the investigator, indicates a medical problem that would preclude study participation including, but not limited to cardiovascular, renal, hepatic, gastrointestinal, respiratory, hematological, endocrine, psychiatric, neurologic, convulsions, or any laboratory abnormality.
  • Have a history of another neurodegenerative disease or significant dementia/severe cognitive problems at screening.
  • Have a slow vial capacity (SVC) less than (\<) 50% predicted value (for sex, age, ethnic origin, and height) at screening.
  • Have significant hepatic abnormalities ( (AST) or alanine aminotransferase (ALT) >2 times (×) (ULN) or total (TBL) >1.5× ULN, in asymptomatic individuals with a history of Gilbert's syndrome, use TBL of >2× ULN).
  • Have a significant renal impairment (estimated less than 60 milliliters per minute per 1.73 square meters (eGFR\<60 mL/min/1.73m²)).
  • If taking riluzole, must be on a stable dose for more than 30 days (prior to Day 1).
  • If taking intravenous or oral edaravone, must have completed 2 treatment cycles (prior to Day 1).
  • Are currently taking or plan to take tofersen for the duration of the study.
  • Show evidence of (HIV) and/or positive human HIV antibodies.
  • Show evidence of and/or positive hepatitis B surface antigen.
  • Have a positive Virus (HCV) antibody test. Participants with a positive HCV antibody test at screening can be included only if a confirmatory HCV Ribonucleic Acid (RNA) test is negative.
  • Have an abnormal blood pressure judged to be clinically significant by the investigator.
  • Have a history of clinically significant back pain, pathological conditions of the back, or back injury (for example, degenerative disease, spinal deformity, or spinal surgery), have a local infection at the intended site of the lumbar puncture (LP) that may predispose to complications or technical difficulty with LP.
  • Are taking or intend to take inhibitors or inducers of CYP1A2, CYP2C9, CYP2C19, CYP2D6, and from 14 days prior to the first dose of any study intervention, or for 5 half lives (whichever is longer), until the final PK sample is collected.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    LY3873862 or Placebo (Cohort 1)

    LY3873862 or placebo administered orally

    Drug: LY3873862 · Drug: Placebo

  • Experimental
    LY3873862 or Placebo (Cohort 2)

    LY3873862 or placebo administered orally with a CYP450 drug cocktail

    Drug: LY3873862 · Drug: CYP450 Drug Cocktail · Drug: Placebo

  • Experimental
    LY3873862 or Placebo (Cohort 3)

    LY3873862 or placebo administered orally with a CYP450 drug cocktail

    Drug: LY3873862 · Drug: CYP450 Drug Cocktail · Drug: Placebo

Interventions

  • DrugLY3873862

    Administered orally

  • DrugCYP450 Drug Cocktail

    CYP450 Drug Cocktail (caffeine, midazolam, flurbiprofen, dextromethorphan and omeprazole) administered orally.

  • DrugPlacebo

    Administered orally

06

What researchers measure

Primary outcomes

  1. Number of Patients with One or More Treatment Emergent Adverse Events Considered by the Investigator to be Related to Study Drug Administration

    Time frame: Baseline, Day 28

Secondary outcomes

  1. Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of LY3873862

    Time frame: Baseline, Day 7

  2. Pharmacokinetics: Maximum Concentration (Cmax) of LY3873862

    Time frame: Baseline, Day 7

07

Study locations

7 sites
  • Sutter Health Research Institute- California Pacific Medical Center, Van Ness Campus
    San Francisco, California 94109, United States
    • · Contact(415) 600-3604
    • Jonathan Katz · Principal investigator
  • University of Colorado Anschutz
    Aurora, Colorado 80045, United States
    • Laura Foster · Principal investigator
  • Georgetown University Medical Center
    Washington D.C., District of Columbia 20007, United States
    • Shakti Nayar · Principal investigator
  • Northwestern University
    Chicago, Illinois 60611, United States
    • · Contact312-503-0671
    • Senda Ajroud-Driss · Principal investigator
  • Healey and AMG Center for ALS at Mass General Hospital
    Boston, Massachusetts 02114, United States
    • · Contact617-724-3914
    • Doreen Ho · Principal investigator
  • Montreal Neurological Institute and Hospital
    Montreal, H3A 2B4, Canada
    • · Contact514-449-8741
    • Angela Genge · Principal investigator
  • Sunnybrook Health Sciences Centre
    Toronto, M4N 3M5, Canada
    • · Contact(416) 480-6100 x687561
    • Agessandro Abrahao · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.

Of 40 industry-sponsored phase 1 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 38. This study's planned 12 months is below that.

Counting every sponsor, half of 70 studies reached it within 21 months; a quarter within 13 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2026
First posted
Oct 20, 2026
StartEst.
Nov 2026
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added, 2 sites removed
Show 5 added (3 United States, 2 Canada)
  • Georgetown University Medical Center · Washington D.C., United States
  • Northwestern University · Chicago, United States
  • Healey and AMG Center for ALS at Mass General Hospital · Boston, United States
  • Montreal Neurological Institute and Hospital · Montreal, Canada
  • Sunnybrook Health Sciences Centre · Toronto, Canada
Show 2 removed
  • University of Kansas Medical Center · Kansas City, United States
  • McGill University · Montreal, Canada
Nov 13, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • University of Colorado Anschutz · Aurora, United StatesContact removed •••2188
Nov 13, 2026
Registered
First appeared on the registry
Oct 20, 2026
Show all 2 updates
  1. Nov 13, 2026
    5 sites added, 2 sites removed
    Show 5 added (3 United States, 2 Canada)
    • Georgetown University Medical Center · Washington D.C., United States
    • Northwestern University · Chicago, United States
    • Healey and AMG Center for ALS at Mass General Hospital · Boston, United States
    • Montreal Neurological Institute and Hospital · Montreal, Canada
    • Sunnybrook Health Sciences Centre · Toronto, Canada
    Show 2 removed
    • University of Kansas Medical Center · Kansas City, United States
    • McGill University · Montreal, Canada
    Site contacts Changed at 1 site. See the sites
    Show the site
    • University of Colorado Anschutz · Aurora, United StatesContact removed •••2188
    + 1 other change: verification date
  2. Oct 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07883590
Responsible party
Sponsor
First posted
Oct 20, 2026
Start date
Nov 2026 (estimated)
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
1-317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion